Schedule 13D ownership disclosure
NovaBay Pharmaceuticals Inc
Common Stock, $0.01 par value · CUSIP: 66987P409
Event date: 2025-10-16
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Framework Ventures IV L.P.Reported CIK 0002028474
Shares: 56,806,080.00 · Class: 45.1%
- Framework Ventures Management LLCReported CIK 0002091751
Shares: 56,806,080.00 · Class: 45.1%
- Framework Ventures IV GP LLCReported CIK 0002092591
Shares: 56,806,080.00 · Class: 45.1%
- Vance SpencerReported CIK 0002092030
Shares: 56,806,080.00 · Class: 45.1%
- Michael Ernest Anderson
Shares: 56,806,080.00 · Class: 45.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001829126-25-008290
- Form type
- SCHEDULE 13D/A
- Filer
- Framework Ventures IV L.P.
- CIK
- CIK 2028474
- Filed
- Oct 20, 2025
- Reporting period
- Oct 16, 2025
- Description
- Schedule 13D beneficial ownership